Seres Theraptc (MCRB) |
|
19.01 -0.79 (-3.99%)
|
02-25 12:20 |
|
Open: |
19.66 |
Pre. Close: |
19.8 |
|
High:
|
20.5 |
Low:
|
18.95 |
|
Volume:
|
347,357 |
Market Cap:
|
1,735M |
|
|
|
|
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to restore health by repairing the function of a dysbiotic microbiome. The company's lead product candidate is the SER-109, which is in Phase III clinical development for preventing recurrence of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study treat ulcerative colitis; SER-401, a microbiome therapeutic candidate, which is in Phase Ib study for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262, to treat an initial recurrence of CDI; and SER-155 to modulate the microbiome and dysbiosis in patients following allogeneic hematopoietic stem cell transplants. The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as collaboration with AstraZeneca. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
21.283 - 21.457 |
21.457 - 21.573 |
|
Low:
|
18.966 - 19.143 |
19.143 - 19.263 |
|
Close:
|
19.563 - 19.843 |
19.843 - 20.032 |
|
Technical analysis |
as of: 2021-02-25 11:48:13 AM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 29.85 One year: 34.92 |
| Support: |
Support1: 18.52 Support2: 15.41 |
| Resistance: |
Resistance1: 25.55 Resistance2: 29.90 |
| Pivot: |
24.54  |
| Moving Average: |
MA(5): 21.42 MA(20): 24.65
MA(100): 27.71 MA(250): 16.84  |
| MACD: |
MACD(12,26): -1.25 Signal(9): -0.56 |
| Stochastic oscillator: |
%K(14,3): 14.65 %D(3): 14.32 |
| RSI: |
RSI(14): 32.05 |
| 52-week: |
High: 38.50 Low: 2.52 Change(%): 528.2 |
| Average Vol(K): |
3-Month: 109349 10-Days: 86835 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.MCRB has closed above bottom band by 6.5%. Bollinger Bands are 52.9% wider than normal. The large width of the bands suggest high volatility as compared to MCRB's normal range. The bands have been in this wide range for 0 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Thu, 25 Feb 2021
Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target - PRNewswire
Wed, 24 Feb 2021
Seres Therapeutics to Host Fourth Quarter 2020 Financial Results and Operational Progress Conference Call on March 2, 2021 - Yahoo Finance
Tue, 19 Jan 2021
Seres Therapeutics to Present SER-109 Phase 3 Mechanistic Data at Keystone Symposium - Business Wire
Thu, 12 Nov 2020
Seres: An Interesting Late-Stage Microbiome Development Company - Seeking Alpha
Mon, 09 Nov 2020
Seres Therapeutics Inc (MCRB) Q3 2020 Earnings Call Transcript - Motley Fool
Mon, 12 Oct 2020
Seres Therapeutics to Present SER-109 Phase 3 ECOSPOR III Study Results at American College of Gastroenterology Annual Scientific Meeting - BioSpace
|
Financial Analysis |
| Growth |
 |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
|
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
 |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
|
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Outperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Neutral |
Price to Earnings: |
Underperform |
| Return on Equity: |
Underperform |
Debt to Equity: |
Outperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
91 |
| Shares Float (M) |
63 |
|
% Held by Insiders
|
9.26 |
|
% Held by Institutions
|
81.20 |
|
Shares Short (K)
|
7,330 |
|
Shares Short P. Month (K)
|
4,540 |
Stock Financials |
|
EPS
|
-1.200 |
|
EPS Est This Year
|
-2.510 |
|
EPS Est Next Year
|
-2.860 |
|
Book Value (p.s.)
|
2.060 |
|
Profit Margin
|
|
|
Operating Margin
|
-384.24 |
|
Return on Assets (ttm)
|
-23.3 |
|
Return on Equity (ttm)
|
-115.1 |
|
Qtrly Rev. Growth
|
-79.8 |
|
Gross Profit (p.s.)
|
-0.500 |
|
Sales Per Share
|
0.255 |
|
EBITDA (p.s.)
|
-0.905 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-90 |
|
Levered Free Cash Flow (M)
|
-44 |
Stock Valuations |
|
PE Ratio
|
-16.44 |
|
PEG Ratio
|
|
|
Price to Book value
|
9.58 |
|
Price to Sales
|
77.35 |
|
Price to Cash Flow
|
-20.06 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
